Scarica l'app Stockscreener
57.49
34.84%
14.86
Pre-mercato:
58.43
0.94
+1.64%
Precedente Chiudi:
$42.63
Aprire:
$49.14
Volume 24 ore:
16.44M
Relative Volume:
7.81
Capitalizzazione di mercato:
$9.16B
Reddito:
$705.14M
Utile/perdita netta:
$-453.90M
Rapporto P/E:
-18.91
EPS:
-3.04
Flusso di cassa netto:
$-551.29M
1 W Prestazione:
+36.33%
1M Prestazione:
+33.60%
6M Prestazione:
+73.21%
1 anno Prestazione:
+20.57%
Intervallo 1D:
$49.13
$57.92
Intervallo di 1 settimana:
$41.95
$57.92
Portata 52W:
$23.95
$57.92
Ionis Pharmaceuticals Inc Stock (IONS) Company Profile
Nome
Ionis Pharmaceuticals Inc
Settore
Industria
Telefono
(760) 931-9200
Indirizzo
2855 GAZELLE COURT, CARLSBAD, CA
Confronta IONS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
IONS
Ionis Pharmaceuticals Inc
|
57.49 | 6.80B | 705.14M | -453.90M | -551.29M | -3.04 |
|
VRTX
Vertex Pharmaceuticals Inc
|
401.00 | 100.25B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
577.90 | 61.55B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
447.00 | 58.53B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
706.41 | 43.59B | 3.06B | 1.28B | 447.35M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
332.04 | 33.67B | 3.81B | -644.79M | -669.77M | -6.24 |
Ionis Pharmaceuticals Inc Stock (IONS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-31 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-07-01 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2025-04-07 | Iniziato | H.C. Wainwright | Buy |
| 2025-03-31 | Iniziato | Redburn Atlantic | Neutral |
| 2024-08-02 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2024-07-24 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-07-16 | Ripresa | Jefferies | Buy |
| 2024-06-14 | Aggiornamento | Bernstein | Underperform → Mkt Perform |
| 2024-04-10 | Aggiornamento | Wolfe Research | Peer Perform → Outperform |
| 2024-01-02 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-10-23 | Aggiornamento | BofA Securities | Underperform → Neutral |
| 2023-09-29 | Iniziato | Raymond James | Strong Buy |
| 2023-07-31 | Aggiornamento | Citigroup | Neutral → Buy |
| 2023-06-07 | Ripresa | Piper Sandler | Overweight |
| 2023-05-04 | Aggiornamento | Citigroup | Sell → Neutral |
| 2023-03-21 | Iniziato | Bernstein | Underperform |
| 2022-12-21 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2022-09-09 | Ripresa | Morgan Stanley | Overweight |
| 2022-07-18 | Ripresa | Oppenheimer | Outperform |
| 2022-03-31 | Ripresa | Piper Sandler | Overweight |
| 2022-03-01 | Iniziato | Citigroup | Sell |
| 2022-03-01 | Iniziato | Guggenheim | Buy |
| 2022-02-01 | Downgrade | BofA Securities | Buy → Underperform |
| 2021-12-14 | Aggiornamento | William Blair | Mkt Perform → Outperform |
| 2021-05-07 | Aggiornamento | UBS | Sell → Neutral |
| 2021-03-01 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2020-12-16 | Iniziato | UBS | Sell |
| 2020-12-15 | Aggiornamento | Cowen | Market Perform → Outperform |
| 2020-09-14 | Ripresa | JP Morgan | Neutral |
| 2020-09-02 | Iniziato | The Benchmark Company | Hold |
| 2020-06-01 | Ripresa | Oppenheimer | Outperform |
| 2020-05-13 | Iniziato | RBC Capital Mkts | Outperform |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-12-13 | Iniziato | Oppenheimer | Outperform |
| 2019-11-13 | Iniziato | BofA/Merrill | Buy |
| 2019-11-07 | Downgrade | Morgan Stanley | Equal-Weight → Underweight |
| 2019-09-10 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2018-08-08 | Reiterato | Stifel | Hold |
| 2018-08-07 | Reiterato | Stifel | Hold |
| 2018-05-08 | Downgrade | Evercore ISI | Outperform → In-line |
| 2017-10-06 | Ripresa | Goldman | Sell |
| 2017-08-17 | Iniziato | Evercore ISI | Outperform |
| 2017-08-09 | Reiterato | Stifel | Hold |
| 2017-03-10 | Downgrade | Goldman | Neutral → Sell |
| 2016-12-28 | Reiterato | BMO Capital Markets | Outperform |
| 2016-12-27 | Reiterato | Leerink Partners | Mkt Perform |
Mostra tutto
Ionis Pharmaceuticals Inc Borsa (IONS) Ultime notizie
Analyzing Ionis Pharmaceuticals Inc. with risk reward ratio charts2025 Major Catalysts & Community Verified Swing Trade Signals - Newser
Ionis Pharmaceuticals, Inc.'s (NASDAQ:IONS) 34% Share Price Surge Not Quite Adding Up - simplywall.st
Using data filters to optimize entry into Ionis Pharmaceuticals Inc.Buy Signal & Accurate Entry/Exit Alerts - Newser
What’s next for Ionis Pharmaceuticals Inc. stock priceTrade Risk Assessment & Precise Entry and Exit Recommendations - Newser
Ionis Pharmaceuticals Inc. stock prediction for this week2025 Support & Resistance & Low Risk Profit Maximizing Plans - Newser
MSD, Ionis trumpet lipid-lowering drug data - pharmaphorum
BMO Capital Upgrades Ionis Pharmaceuticals to Outperform From Market Perform, Adjusts PT to $70 From $40 - MarketScreener
Will Ionis Pharmaceuticals Inc. bounce back from current supportPortfolio Value Report & Expert Approved Momentum Ideas - Newser
Ionis reports topline outcomes from Phase III trials of olezarsen for sHTG - Yahoo Finance
Ionis Pharmaceuticals shares rise 1.74% premarket after positive Phase 3 study results for olezarsen. - AInvest
Has Ionis Pharmaceuticals Inc. formed a bullish divergenceBuy Signal & Fast Entry Momentum Alerts - Newser
Ionis looks to expand use of lipid-lowering drug after trial hits goal - BioPharma Dive
Narrow-Moat Ionis Expands Its Cardiology and Neurology Portfolio; Positive Long-Term Outlook - Morningstar
Visualizing Ionis Pharmaceuticals Inc. stock with heatmaps2025 Top Gainers & Daily Profit Maximizing Tips - Newser
Ionis reports sHTG win while Arrowhead inks Novartis deal - BioWorld MedTech
IONS Stock Soars: Time to Buy or Stay Cautious? - timothysykes.com
More Ways to Cut Cholesterol, Triglycerides Are Coming. This Stock Took Off. - Barron's
Ionis Looks Set To Own Its First Blockbuster - insights.citeline.com
Ionis to present at upcoming investor conferences - Business Wire
IONS Stock Soars 34% To Hit February 2021 Highs After Medicine Shows Positive Effect On Elevated Triglyceride Levels In Late-Stage Studies - Stocktwits
Ionis Pharmaceuticals: A High-Conviction Buy Amid a Pivotal Data and Launch Timeline in 2025 - AInvest
FDA Greenlights Ionis’ Dawnzera, Shares Soar - StocksToTrade
Ionis shares surge after drug to lower blood fat shows promise in trials - TradingView
Ionis Pharmaceuticals and the Breakthrough Potential of Olezarsen in Severe Hypertriglyceridemia - AInvest
FDA Grants Approval: Ionis Gains Momentum - timothysykes.com
Ionis Pharma Shares Rise After Reporting 'Positive' Olezarsen Data in Severe Hypertriglyceridemia - MarketScreener
Ionis Pharmaceuticals stock rockets 31% to new 52-week high on breakthrough news - TradingView
Real time breakdown of Ionis Pharmaceuticals Inc. stock performancePortfolio Performance Report & Long-Term Investment Growth Plans - Newser
Air Lease, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals And Other Big Stocks Moving Higher On Tuesday - inkl
Ionis Pharma's Investigational Drug Shows Promise For Triglyceride And Pancreatitis Reduction - Yahoo Finance
Ionis Pharmaceuticals stock holds steady as Stifel maintains $43 target - Investing.com
Ionis Pharmaceuticals stock hits 52-week high at 49.3 USD - Investing.com
Ionis Pharmaceuticals: A High-Conviction Biotech Play Amid Triglyceride-Lowering Breakthroughs and Undervalued Pipeline Potential - AInvest
Transcript : Ionis Pharmaceuticals, Inc.Special Call - MarketScreener
Ionis Pharmaceuticals’ Dawnzera Approval Boosts Stock - StocksToTrade
Ionis Pharma Hits Four-Year High On A 'Home Run' In Triglycerides Treatment - inkl
Positive Phase III results for Ionis’ olezarsen in severe hypertriglyceridemia - The Pharma Letter
Ionis shares jump after drug lowers blood fat levels in advanced trials - TradingView
PepsiCo, Ionis Pharma, United Therapeutics - TradingView
Sector Update: Health Care Stocks Mixed Premarket Tuesday - MarketScreener
Sector Update: Health Care - MarketScreener
Ionis Pharmaceuticals Incannounces positive results from phase 3 studies of olezarsenSEC filing - MarketScreener
Leerink Partners Adjusts Price Target on Ionis Pharmaceuticals to $62 From $56, Maintains Outperform Rating - MarketScreener
Olezarsen significantly reduces triglycerides and acute pancreatitis events in landmark pivotal studies for people with severe hypertriglyceridemia (sHTG) - BioSpace
Ionis Pharmaceuticals (IONS) Soars 17.32% on FDA Approval - AInvest
Ionis stock soars after olezarsen shows 85% reduction in pancreatitis events - Investing.com
What the charts say about Ionis Pharmaceuticals Inc. todayWeekly Earnings Recap & AI Based Buy/Sell Signal Reports - Newser
Ionis posts late-stage trial win for lipid drug (IONS:NASDAQ) - Seeking Alpha
Ionis says 'unprecedented' data support Tryngolza's label expansion in severe triglyceride disease - Endpoints News
How to use a screener to detect Ionis Pharmaceuticals Inc. breakouts2025 Technical Patterns & Consistent Profit Trade Alerts - Newser
Ionis Pharmaceuticals (IONS) Gains FDA Approval for HAE Drug, Piper Sandler Lifts Target - Yahoo Finance
Ionis Pharmaceuticals Inc Azioni (IONS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
4.10%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):